HCM & HRIS

Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring

May 28, 2026
www.ETHRWorld.com
No Comments
  • Published On May 14, 2026 at 11:19 PM IST

< />By Sahil Pandey and Siddhi Mahatole<br><br>Japan’s Takeda Pharmaceutical plans to cut about 4,500 jobs in fiscal year 2026, as part of a restructuring to centralize corporate functions and reduce costs.<br><br><!– PROMOSLOT_M –> The company expects annual savings of more than 200 ‌billion yen ($1.27 billion) ⁠by fiscal ⁠2028, with about 100 billion yen expected in fiscal 2026, it said in its fourth-quarter earnings presentation on Wednesday.<br><br> A Takeda spokesperson told Reuters that the number represents less than 10% of its global workforce and does not include hiring plans.<br><br><!– PROMOSLOT_M –><div class=” article-detail-ad-slot=”” captionrendered=”1″ data-src=”https://etimg.etb2bimg.com/photo/131100463.cms” height=”442″ loading=”eager” src=”https://hr.economictimes.indiatimes.com/images/default.jpg” width=”590″></img></p> </div> <p> The company currently has about 2,200 open roles and expects to create new jobs during the year, which it ⁠will prioritize ‌to fill with internal candidates, the spokesperson said.</p> <p> Takeda has been in the midst of a years-long overhaul following its $62 billion ⁠acquisition of Shire in 2019, which expanded its global footprint but added debt and complexity.</p> <p> The company expects higher selling, general and administrative, and R&D expenses linked to upcoming product launches, including narcolepsy treatment oveporexton, blood disorder drug rusfertide and psoriasis pill zasocitinib, but said much of the increase would be offset by the restructuring program.</p> <p> It anticipates restructuring costs of around 170 billion yen in fiscal ‌2026, with lower amount expected in the next two years, according to the presentation.</p> <p> Jefferies analyst Stephen Barker said investor focus is likely to shift to ⁠three late-stage product launches expected over the next 12-18 months.</p> <p> Takeda’s announcement comes after Danish drugmaker Novo Nordisk said in September it would slash 9,000 jobs in a bid to fend off intense competition from U.S. rival Eli Lilly.</p> <p> Earlier this month, Takeda’s immune disease drug met the main goal in a mid-to late-stage study, with the company planning to seek approval in the U.S. this year. ($1 = 157.8300 yen) (Reporting by Sahil Pandey and Siddhi Mahatole in Bengaluru; Editing by Shilpi Majumdar)</p> <div> <div> <ul> <li><a href=Reuters

  • Published On May 14, 2026 at 11:19 PM IST

Join the community of 2M+ industry professionals.

Subscribe to Newsletter to get latest insights & analysis in your inbox.

All about industry right on your smartphone!

  • Download the App and get the Realtime updates and Save your favourite articles.

Leave a Reply

Your email address will not be published. Required fields are marked *